siRNA (KRAS)

siRNA (KRAS) refers to a class of RNA interference (RNAi)-based therapeutic agents designed to silence the expression of the KRAS oncogene, a critical driver in many human cancers. These drugs utilize small interfering RNA (siRNA) molecules that are complementary to the KRAS messenger RNA (mRNA). Upon delivery into tumor cells, the siRNA is incorporated into the RNA-induced silencing complex (RISC), which then binds to and cleaves the target KRAS mRNA, preventing the translation of the KRAS protein. This approach is particularly significant because KRAS has historically been considered "undruggable" by traditional small molecules. Development efforts, most notably by Silexion Therapeutics (formerly Silenseed), have produced candidates like siG12D-LODER, which uses a biodegradable PLGA microparticle system for local, sustained delivery in pancreatic cancer, and SIL-204, which targets specific mutations such as G12D and G12V.

Other names

KRAS siRNAsiRNA targeting KRASsiRNA-KRAS